The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-18. Anything still debated is marked as such rather than presented as settled.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
In biology, a substitution model, also called models of sequence evolution, are Markov models that describe changes over evolutionary time. These models describe evolutionary changes in macromolecules, such as DNA sequences or protein sequences, that can be represented as a sequence of symbols (e.g., A, C, G, and T in the case of DNA or the 20 "standard" proteinogenic amino acids in the case of proteins). Substitution models are used to calculate the likelihood of phylogenetic trees using multiple sequence alignment data. Thus, substitution models are central to maximum likelihood estimation of phylogeny as well as Bayesian inference in phylogeny. Estimates of evolutionary distances (numbers of substitutions that have occurred since a pair of sequences diverged from a common ancestor) are typically calculated using substitution models (evolutionary distances are used as input for distance methods such as neighbor joining). Substitution models are also central to phylogenetic invariants because they are necessary to predict site pattern frequencies given a tree topology. Substitution models are also necessary to simulate sequence data for a group of organisms related by a specific tree.
=== Board game === Main articles: Le Havre (board game) Le Havre is a board game about the development of the town of Le Havre. It was inspired by the games Caylus and Agricola and was developed in December 2007.
"p53 Knowledgebase". Lane Group at the Institute of Molecular and Cell Biology (IMCB), Singapore. Archived from the original on 2006-01-03. Retrieved 2008-04-06. GeneReviews/NCBI/NIH/UW entry on Li-Fraumeni Syndrome TUMOR PROTEIN p53 @ OMIM p53 restoration of function p53 @ The Atlas of Genetics and Cytogenetics in Oncology and Haematology TP53 Gene @ GeneCards p53 News provided by insciences organisation Goodsel DS (2002-07-01). "p53 Tumor Suppressor". Molecule of the Month. RCSB Protein Data Bank. Retrieved 2008-04-06. Soussi T. "p53 Web Site". Retrieved 2008-04-06. Living LFS A non-profit Li-Fraumeni Syndrome patient support organization The George Pantziarka TP53 Trust A support group from the UK for people with Li-Fraumeni Syndrome or other TP53-related disorders IARC TP53 Somatic Mutations database maintained at IARC, Lyon, by Magali Olivier PDBe-KB provides an overview of all the structure information available in the PDB for Human P53. scientific animation conformational changes of p53 upon binding to DNA
==== Unfinished Tales and The History of Middle-earth ==== In 1980, Christopher Tolkien published a collection of more fragmentary material, under the title Unfinished Tales of Númenor and Middle-earth. In subsequent years (1983–1996), he published a large amount of the remaining unpublished materials, together with notes and extensive commentary, in a series of twelve volumes called The History of Middle-earth. They contain unfinished, abandoned, alternative, and outright contradictory accounts, since they were always a work in progress for Tolkien and he only rarely settled on a definitive version for any of the stories. There is not complete consistency between The Lord of the Rings and The Hobbit, the two most closely related works, because Tolkien never fully integrated all their traditions into each other. He commented in 1965, while editing The Hobbit for a third edition, that he would have preferred to rewrite the book completely because of the style of its prose.
Sources: en.wikipedia.org
== Chestnut mimics == Bay horses also have reddish coats, but they have a black mane, tail, legs and other point coloration. The presence of true black points, even if obscured by white markings, means that a horse is not chestnut. Seal brown or dark bay horses are not chestnut but may be confused with a liver chestnut. Those unfamiliar with horse coat color terminology often call most horses "brown". including chestnuts. Brown, which may be difficult to distinguish visually from dark bay, is always accompanied by black points. Liver chestnuts, in particular, are mistakenly called brown or "seal brown". Silver bay horses typically have chocolate- to red-brown bodies with silvered mane, tail, and legs. The flat reddish-brown color and lack of easily identified black points can confuse even knowledgeable horse persons. Silver dapple horses usually hint at black or dark gray pigment at the roots of the mane and tail, and where their silver points end on the legs. Silvers look a bit "off"-chestnut. To further confuse matters, some flaxen chestnuts have silverish streaks in their manes and tails. However, genetic testing can clarify matters.
Raw veneer has no backing on it and can be used with either side facing up. The two sides will appear different when a finish has been applied due to the cell structure of the wood. Paper backed veneer is as the name suggests, veneers that are backed with paper. The advantage to this is it is available in large sizes, or sheets, as smaller pieces are joined prior to adding the backing. This is helpful for users that do not wish to join smaller pieces of raw veneers together. This is also helpful when veneering curves and columns as the veneer is less likely to crack. Phenolic backed veneer is less common and is used for composite, or artificial wood veneers. Due to concern for the natural resource, this is becoming more popular. It too has the advantage of being available in sheets, and is also less likely to crack when being used on curves. Laid up veneer is raw veneer that has been joined to make larger pieces. The process is time-consuming and requires great care, but is not difficult and requires no expensive tools or machinery. Veneers can be ordered through some companies already laid up to any size, shape or design. Reconstituted veneer is made from fast-growing tropical species. Raw veneer is cut from a log, and dyed if necessary. Once dyed, the sheets are laminated together to form a block. The block is then sliced so that the edges of the laminated veneer become the “grain” of the reconstituted veneer. Wood on Wood Also called 2-ply is a decorative wood veneer face with a utility grade wood backer applied at an opposing direction to the face veneer.
2 CO(NH2)2 → HN(CONH2)2 + NH3 Under related conditions, pyrolysis of urea affords triuret O=C(−N(H)−C(=O)−NH2)2. In general, organic biurets (those with alkyl or aryl groups in place of one or more H atoms) are prepared by trimerization of isocyanates. For example, the trimer of 1,6-hexamethylene diisocyanate is also known as HDI-biuret. In the anhydrous form, the molecule is planar and unsymmetrical in the solid state owing to intramolecular hydrogen bonding. The terminal C–N distances of 1.327 and 1.334 Å are shorter than the internal C–N distances of 1.379 and 1.391 Å. The C=O bond distances 1.247 and 1.237 Å. It crystallizes from water as the monohydrate.
== History == In 1872, Anders Daae and Christian Horrebow Homann reported an epidemic of pleurodynia occurring in Bamble Municipality in Norway, giving rise to the name "Bamble disease". Subsequent reports, published only in Norwegian, referred to the disease by this name. Niels Ryberg Finsen also described the disease in Iceland in 1874. In 1933, Ejnar Sylvest gave a doctoral thesis describing a Danish outbreak of this disease on Bornholm Island entitled "Bornholm disease-myalgia epidemica", and this name has persisted. In 1949 the Coxsackie B virus was isolated and established as an etiology of Bornholm disease.
=== Cells === Wandering cells - cells that migrate into the tissue from blood stream in response to a variety of stimuli; for example, immune system blood cells causing inflammatory response. Fixed cells - cells that are permanent inhabitants of the tissue. Fibroblast - produce and secrete the organic parts of the ground substance and extracellular fibers of the matrix.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.